Minerva Neurosciences: Klotho Advances Gene Therapy KLTO-202 for ALS Breakthrough

Klotho Neurosciences Advances Gene Therapy for ALS: A Promising Breakthrough

Klotho Neurosciences, Inc. is making significant strides in developing KLTO-202, an investigational gene therapy designed to treat amyotrophic lateral sclerosis (ALS). The company announces its transition to the manufacturing and process development stages for this innovative therapy, following a successful licensing agreement with the Autonomous University of Barcelona. This partnership grants Klotho access to a unique RNA splice variant of the human alpha-Klotho gene, which is central to the development of gene therapies aimed at neurodegenerative diseases. The alpha-Klotho gene is noteworthy for its production of two protein isoforms—membrane-bound Klotho (m-KL) and secreted alpha-Klotho (s-KL)—with the latter being particularly abundant in the brain and spinal cord. Research indicates that s-KL has neuroprotective properties that may help mitigate oxidative stress and neuroinflammation, important factors in the progression of ALS.

Klotho Neurosciences has spent the last two years conducting extensive animal studies that showcase the therapeutic potential of amplifying s-KL levels through gene therapy. The company’s research findings, published in peer-reviewed journals, suggest that elevating s-KL can yield beneficial outcomes in models of rapid aging, Alzheimer's disease, and ALS. This emerging body of evidence strengthens the company’s case for the efficacy of KLTO-202 in clinical settings. To facilitate the next phase of development, Klotho anticipates an eight-month timeline for process development and manufacturing, followed by an additional four to six months for FDA consultations and safety studies. The ultimate goal is to file an investigational new drug application (IND) and initiate Phase I/II clinical trials in ALS patients by the third quarter of the following year.

CEO Dr. Joseph Sinkule emphasizes the efficiency of their production methods, particularly in the creation of the adeno-associated virus (AAV) vector that is crucial for delivering the s-KL gene directly to motor neurons, the very cells severely affected by ALS. By enhancing the levels of s-KL protein in these neurons, Klotho aims to provide a protective effect against the damage that leads to muscle paralysis and eventual death. Given the aggressive nature of ALS, Klotho's advancements in gene therapy represent a critical development in the race to find effective treatments for this devastating condition, highlighting the urgency and importance of ongoing research in neurodegenerative disorders.

In related news, Klotho's commitment to innovation in gene therapy reflects a broader trend in the biopharmaceutical industry, where companies are increasingly focusing on genetic-based treatments for complex diseases. As more research emerges in the gene therapy space, the potential for transformative therapies continues to grow, offering hope to patients facing previously untreatable conditions. With KLTO-202, Klotho Neurosciences stands at the forefront of a promising new frontier in ALS treatment.